Assembly Biosciences Inc V7B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €13.55
- Day Range
- €13.30–13.30
- 52-Week Range
- €14.30–18.00
- Bid/Ask
- €12.90 / €14.10
- Market Cap
- €84.40 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 65
- Website
- https://www.assemblybio.com
Comparables
Valuation
Metric
|
V7B
|
ATXS
|
BPMC
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.66 | 2.54 | 17.90 |
Price/Sales | 3.55 | — | 15.69 |
Price/Cash Flow | — | — | — |
Price/Earnings
V7B
ATXS
BPMC
Financial Strength
Metric
|
V7B
|
ATXS
|
BPMC
|
---|---|---|---|
Quick Ratio | 2.65 | 21.67 | 3.48 |
Current Ratio | 2.74 | 21.87 | 3.71 |
Interest Coverage | — | — | −8.43 |
Quick Ratio
V7B
ATXS
BPMC
Profitability
Metric
|
V7B
|
ATXS
|
BPMC
|
---|---|---|---|
Return on Assets (Normalized) | −43.57% | −24.27% | −24.11% |
Return on Equity (Normalized) | −104.16% | −39.29% | −104.04% |
Return on Invested Capital (Normalized) | −109.82% | −30.47% | −41.57% |
Return on Assets
V7B
ATXS
BPMC
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Qzmczmtyp | Tlczn | $518.0 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Btghxhbf | Vjymvjc | $119.3 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Yqtwwcwq | Vcpnwl | $114.7 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Tdcxynjf | Yhmwttl | $34.9 Bil | |||
argenx SE ADR
ARGX
| Qxtwbmwb | Tzdm | $32.9 Bil | |||
BioNTech SE ADR
BNTX
| Jnvhyhlf | Pbm | $28.3 Bil | |||
Moderna Inc
MRNA
| Gcqfpdc | Hpjhl | $24.3 Bil | |||
United Therapeutics Corp
UTHR
| Syfndhr | Fvrg | $15.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Wrlcbkx | Pdzskq | $13.3 Bil | |||
Incyte Corp
INCY
| Nnbhppvbg | Mstfxk | $13.0 Bil |